Jeff Sternlicht: The Most Powerful Time to Lower Cholesterol Is Before Anyone Thinks You Need It
Jeff Sternlicht, Emergency Physician and Medical Director at Vituity, shared a post on LinkedIn about a recent article by Dinesh K. Kalra et al, published in Journal of Clinical Lipidology:
“The Most Powerful Time to Lower Cholesterol
Is Before Anyone Thinks You Need It
We often think cholesterol treatment works best after someone already has heart disease.
But a new meta-analysis published in the Journal of Clinical Lipidology suggests something surprising.
Lowering LDL cholesterol may actually reduce cardiovascular risk even more in primary prevention than in secondary prevention.
Across pooled randomized trials, each 1 mmol/L (≈39 mg/dL) reduction in LDL was associated with about a 30% reduction in major cardiovascular events.
That relative risk reduction is greater than what is typically seen in secondary prevention populations.
Why would that be?
Because atherosclerosis is a lifetime exposure disease.
Plaque does not suddenly appear the day before a heart attack.
It builds quietly over decades as ApoB-containing lipoproteins circulate through the arteries.
Lowering LDL later in life can help stabilize plaque that already exists.
Lowering LDL earlier in life can prevent much of that plaque from forming in the first place.
Those are two very different biological situations.
Two people can have the same LDL today.
One spent 40 years with LDL around 160.
The other spent 40 years closer to 80.
Their arteries are not the same.
This is why modern cardiovascular risk reduction is increasingly focused on earlier detection and earlier action.
Look for plaque earlier.
Identify hidden risk.
Lower lifetime ApoB exposure.
The goal is not just treating heart disease.
The goal is preventing the first heart attack entirely.
Disclaimer: Views are my own. This post is for educational purposes only and is not medical advice.”
Title: Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis
Authors: Dinesh K. Kalra, Kausik K. Ray, Archna Bajaj, Pamela R. Kushner, Meredith L. Wilcox, Mary R. Dicklin, Carol F. Kirkpatrick, Kevin C. Maki
Read the Full Article on Journal of Clinical Lipidology
Stay updated with Hemostasis Today.
-
Apr 30, 2026, 18:19Deva Nanda TK: A Practical Overview of Dural Sinuses and The Venous Drainage of the Brain
-
Apr 30, 2026, 18:08Amrit Kaur Kaler: The Hidden Genetic Drivers of Thrombosis
-
Apr 30, 2026, 18:06Alejandro González Veliz: The Most Dangerous Mistake After Getting a Stent
-
Apr 30, 2026, 18:03Carmen Ruiz: First Arterial Mechanical Thrombectomy in New Zealand Using the ARTIX System
-
Apr 30, 2026, 17:52Simon Senanu: von Willebrand Disease May Be Missed Despite Normal Tests
-
Apr 30, 2026, 17:20José Antonio García Erce: Why Healthy Older Adults Should Keep Donating Blood?
-
Apr 30, 2026, 17:13Paul Logan: Decoding the Words ‘He’s on blood thinners’
-
Apr 30, 2026, 17:01Jason Andrade: A Decade-Long Quest Proves Early Ablation Halves Persistent AF Burden
-
Apr 30, 2026, 16:56Oliver Maracic: Could Co-Targeting ALK with FAK/PYK2 Help Mitigate the High VTE Burden Seen in ALK with NSCLC